Drug intelligence / Profile preview

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK)

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted is a two-component vaccine consisting of an H5N1 immunizing antigen (as a suspension) and an AS03 adjuvant (as an oil-in-water emulsion). The vaccine is prepared by combining the H5N1 antigen suspension with the AS03 adjuvant emulsion. The H5N1 antigen is derived from virus grown in eggs, which is inactivated with ultraviolet light followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate. The AS03 adjuvant system enhances the vaccine-induced immune response and contains DL-α-tocopherol (vitamin E), squalene, and polysorbate 80 in an oil-in-water emulsion. This adjuvant system activates multiple innate immune pathways including interferon and JAK-STAT signaling, Fcγ receptor-mediated phagocytosis, and antigen processing and presentation, which leads to superior adaptive responses against the vaccine antigen.

Brand names
AdjupanrixPandemrix
Other names
AS03-Adjuvanted H5N1 Pandemic Influenza VaccineAS-03-Adjuvanted H5N1 Pandemic Influenza VaccineAS 03-Adjuvanted H5N1 Pandemic Influenza Vaccine
02

Targets

HA-TCR (Influenza hemagglutinin-specific T-cell receptor)Hemagglutinin-specific B-cell receptorHA (Hemagglutinin)

Beyond the preview

Go deeper on Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (GSK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call